Panbela Therapeutics, Inc. (PBLA)
| Market Cap | 38.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.86M |
| Shares Out | 7.89M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $4.04 |
| Previous Close | $4.06 |
| Change ($) | -0.02 |
| Change (%) | -0.49% |
| Day's Open | 4.12 |
| Day's Range | 3.90 - 4.20 |
| Day's Volume | 55,192 |
| 52-Week Range | 2.49 - 4.50 |
News
MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients w...
About PBLA
Panbela Therapeutics, a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics Inc. in December 2020. Panbela Therapeutics Inc. was founded i... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Michael Cullen | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol PBLA |